# Egyptian Henbane (Hyoscyamus muticus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/egyptian-henbane-hyoscyamus-muticus
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** Hyoscyamus muticus L., Egyptian Henbane, Altropine Henbane, Desert Henbane, Banj (Arabic folk name), Hyoscyamus boveanus

## Overview

Hyoscyamus muticus contains tropane alkaloids — primarily scopolamine (13.79% of alkaloid fraction) and atropine (3.80%) — alongside a dominant phenolic fraction led by chlorogenic acid (17,108.3 µg/g), collectively producing anticholinergic, antispasmodic, and antioxidant effects. In vitro studies report potent urease inhibition with an IC₅₀ of 5.6 ± 1.20 µg/mL and 91.35% inhibition, and [antioxidant activity](/ingredients/condition/antioxidant) (IC₅₀ 6.12 µg/mL) exceeding that of the synthetic standard BHT (IC₅₀ 9.21 µg/mL).

## Health Benefits

- **Anticholinergic Pain and Spasm Relief**: Atropine and scopolamine, the dominant alkaloids, block muscarinic [acetylcholine](/ingredients/condition/cognitive) receptors (M1–M3), reducing smooth muscle spasm and visceral pain — the pharmacological basis of its traditional use as a sedative and antispasmodic in Yemeni and Egyptian ethnomedicine.
- **Antioxidant Protection**: The methanolic extract demonstrated stronger antioxidant activity than BHT across DPPH, ABTS, reducing power, and phenanthroline assays, driven primarily by the exceptionally high chlorogenic acid content (17,108.3 µg/g), which scavenges [reactive oxygen species](/ingredients/condition/antioxidant) and chelates transition metals.
- **Urease Inhibition**: The ethanolic extract achieved 91.35% urease inhibition at an IC₅₀ of 5.6 µg/mL in vitro, a property relevant to suppressing Helicobacter pylori virulence and reducing urea-mediated tissue damage; hyperoside showed the strongest molecular docking binding energy at −7.9 kcal/mol.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Potential**: Polyphenols including quercetin (120 µg/g), luteolin, kaempferol, and rosmarinic acid (125.2 µg/g) are established NF-κB and COX pathway modulators, providing a phytochemical basis for the plant's traditional use in managing inflammatory pain conditions.
- **Sedative and CNS Depression**: Scopolamine, as a centrally penetrating muscarinic antagonist, produces sedation, reduces motion sickness, and has historically been used as a preanesthetic agent; its presence in H. muticus extracts underlies traditional sedative applications in regional folk medicine.
- **[Antimicrobial](/ingredients/condition/immune-support) Activity**: Phenolic acids such as gallic acid (125.25 µg/g), protocatechuic acid (1,108.3 µg/g), and p-coumaric acid (875 µg/g) disrupt microbial cell membranes and inhibit biofilm formation, contributing to reported antimicrobial effects documented in phytochemical studies.
- **[Cardiovascular](/ingredients/condition/heart-health) and Smooth Muscle Modulation**: Atropine's competitive antagonism at cardiac M2 receptors increases heart rate and is used clinically in bradycardia; at sub-therapeutic traditional doses, this alkaloid load may contribute to mild cardiovascular stimulation and bronchodilation observed anecdotally in ethnobotanical records.

## Mechanism of Action

The primary pharmacological activity of Hyoscyamus muticus is driven by tropane alkaloids — scopolamine and atropine — which competitively and reversibly block muscarinic [acetylcholine](/ingredients/condition/cognitive) receptors (subtypes M1 through M5), inhibiting parasympathetic neurotransmission at smooth muscle, exocrine glands, and the central nervous system, producing antispasmodic, antisecretory, and sedative effects. At the phenolic level, chlorogenic acid and rosmarinic acid inhibit [lipid peroxidation](/ingredients/condition/antioxidant) and scavenge superoxide and hydroxyl radicals through hydrogen atom transfer and single electron transfer mechanisms, while quercetin, luteolin, and kaempferol modulate NF-κB nuclear translocation and suppress [pro-inflammatory cytokine](/ingredients/condition/inflammation) gene expression (TNF-α, IL-6, IL-1β). Hyperoside, the leading urease inhibitor by molecular docking (ΔG = −7.9 kcal/mol), binds the active site of bacterial urease through hydrogen bonding and hydrophobic interactions, blocking ammonia production critical to Helicobacter pylori's gastric colonization and pathogenicity. Fatty acid constituents — palmitic acid (32.56%), linolenic acid (21.34%), and linoleic acid (11.24%) — may contribute to membrane-targeted [antimicrobial](/ingredients/condition/immune-support) action and serve as substrates for eicosanoid biosynthesis pathways relevant to inflammation resolution.

## Clinical Summary

No published human clinical trials evaluating Hyoscyamus muticus extracts for any indication have been identified in the available scientific literature. The pharmacological activities of its principal alkaloids — scopolamine and atropine — are extensively documented in clinical medicine as isolated pharmaceutical agents, lending indirect pharmacological plausibility to traditional pain and sedative uses of the whole plant. However, the clinical behavior of the whole-plant extract, including effective dose thresholds, bioavailability of alkaloids and phenolics from crude preparations, and the net pharmacodynamic interaction between stimulatory alkaloids and [antioxidant](/ingredients/condition/antioxidant) polyphenols, remains uncharacterized in human subjects. Confidence in any specific therapeutic claim for H. muticus preparations remains very low, and all available efficacy data derive from in vitro models with uncertain clinical relevance.

## Nutritional Profile

Hyoscyamus muticus is not a dietary food source and has no conventional nutritional profile; its relevance lies in its concentrated phytochemical composition. The dominant phenolic compound is chlorogenic acid at an extraordinarily high concentration of 17,108.3 µg/g dry weight, followed by protocatechuic acid (1,108.3 µg/g), p-coumaric acid (875 µg/g), rutin (269.25 µg/g), and rosmarinic acid (125.2 µg/g). The fatty acid profile of the whole plant includes palmitic acid (32.56%), linolenic acid (omega-3, 21.34%), and linoleic acid (omega-6, 11.24%), suggesting a nutritionally relevant lipid composition if the plant were consumed safely in quantity. Bioavailability of phenolics from crude extracts is expected to be moderate and subject to matrix effects; the bioavailability of tropane alkaloids (scopolamine and atropine) from oral consumption is well-established as high (>80% for atropine), meaning even small amounts of the plant can deliver pharmacologically active alkaloid doses.

## Dosage & Preparation

- **Traditional Whole-Herb Decoction (Yemen/Egypt)**: Leaves and aerial parts boiled in water; applied topically to painful areas or taken in small oral doses as a sedative — precise dosing is undocumented and highly variable across regional practice.
- **Methanolic Extract (Research Use)**: Standardized extracts using 70–80% methanol have been employed in phytochemical studies; these are not available as consumer supplements and are for laboratory use only.
- **Ethanolic Extract (Research Use)**: Ethanol-based extracts used in urease inhibition assays at concentrations demonstrating IC₅₀ of 5.6 µg/mL — no safe oral dose for humans has been established.
- **Alkaloid Fraction**: Scopolamine and atropine are extracted and used as isolated pharmaceutical agents at precise doses (e.g., scopolamine patches 1 mg/72 h; atropine 0.5–1 mg IV) — these purified forms should never be self-dosed from crude plant material.
- **CRITICAL NOTE — No Safe Supplemental Dose Established**: Due to narrow therapeutic windows of tropane alkaloids, no standardized supplemental dose of H. muticus crude extract can be recommended; traditional use without medical supervision carries serious risk of anticholinergic toxicity.
- **Standardization**: No commercial standardized extract form exists; no standardization percentage for alkaloid or phenolic content has been validated for therapeutic use.

## Safety & Drug Interactions

Hyoscyamus muticus poses significant safety risks due to its high content of scopolamine and atropine, both potent anticholinergic agents with narrow therapeutic windows; symptoms of toxicity include dry mouth, blurred vision, urinary retention, tachycardia, hyperthermia, confusion, hallucinations, and in severe cases, respiratory depression and death — a toxidrome known as anticholinergic syndrome. The plant is absolutely contraindicated in individuals with glaucoma, benign prostatic hyperplasia, myasthenia gravis, tachyarrhythmias, pyloric stenosis, and during pregnancy (FDA Category C/D equivalent; atropine crosses the placenta causing fetal tachycardia) and lactation. Critical drug interactions include potentiation of anticholinergic effects with antihistamines (diphenhydramine), tricyclic antidepressants, antipsychotics, and antispasmodics; antagonism of prokinetic agents (metoclopramide); and unpredictable interactions with CNS depressants including opioids and benzodiazepines. No maximum safe dose has been established for crude plant preparations, and self-medication with any form of H. muticus is strongly inadvisable without medical supervision; its traditional use should be understood in the context of historical necessity, not modern safety standards.

## Scientific Research

The current evidence base for Hyoscyamus muticus consists exclusively of in vitro laboratory studies, GC-MS and LC-ESI-MS/MS phytochemical analyses, and computational molecular docking simulations — no human clinical trials or animal intervention studies have been published in peer-reviewed literature as of the latest available data. Phytochemical characterization studies have rigorously quantified 19 phenolic compounds and confirmed the presence of scopolamine and atropine as major alkaloids, providing pharmacologically coherent data. [Antioxidant](/ingredients/condition/antioxidant) assays using DPPH, ABTS, β-carotene bleaching, and phenanthroline methods consistently demonstrate potent radical scavenging, with the extract outperforming BHT (IC₅₀ 6.12 vs. 9.21 µg/mL), while urease inhibition at IC₅₀ 5.6 µg/mL with 91.35% maximal inhibition represents strong in vitro bioactivity. The evidence tier is purely preclinical, and extrapolation of these findings to human therapeutic outcomes must be approached with caution; clinical translation requires dose-ranging pharmacokinetic studies and controlled human trials that do not currently exist.

## Historical & Cultural Context

Hyoscyamus muticus has been used in Egyptian and Arabian traditional medicine for centuries, with documented ethnobotanical uses in the Sinai Peninsula and upper Egypt as an analgesic, sedative, and antispasmodic for toothache, abdominal pain, and rheumatic conditions. In Yemeni herbalism, the plant — known regionally under various Arabic folk names — has been prepared as smoked herb, topical poultice, or decoction to manage pain and induce sleep, reflecting the broad traditional understanding of its potent CNS-active properties. The genus Hyoscyamus has historical significance in medieval Islamic medicine, referenced by Ibn Sina (Avicenna) in the Canon of Medicine as a cautiously used narcotic and analgesic, with warnings about toxicity that remain relevant today. Ancient Egyptian texts and later Arab pharmacopoeias recognized henbane species for their ability to dull pain and produce unconsciousness, and the plant was historically implicated in both medicinal and poisonous applications across Mediterranean and Middle Eastern cultures.

## Synergistic Combinations

Within traditional formulations, H. muticus has been combined with other analgesic herbs such as Nigella sativa and frankincense (Boswellia sacra) in Yemeni pain management, where [anti-inflammatory](/ingredients/condition/inflammation) terpenoids from Boswellia may complement the antispasmodic alkaloid activity of henbane while potentially broadening the therapeutic window. The chlorogenic acid and rutin content of H. muticus may exhibit additive [antioxidant](/ingredients/condition/antioxidant) synergy with vitamin C and flavonoid-rich herbs (e.g., Moringa oleifera) through complementary radical scavenging mechanisms operating across different oxidation potentials. From a pharmacological standpoint, combination with gastroprotective agents such as deglycyrrhizinated licorice (DGL) has theoretical merit when considering the plant's urease-inhibiting phenolics alongside ulcer management, though no empirical data exist to confirm synergistic efficacy or safety in combination.

## Frequently Asked Questions

### What is Hyoscyamus muticus used for in traditional medicine?

In traditional Yemeni and Egyptian herbalism, Hyoscyamus muticus has been used primarily as a pain reliever and sedative for conditions including toothache, abdominal cramping, and rheumatic pain. Preparations typically involved decoctions of the aerial parts or topical poultices, with the pharmacological activity attributed to its tropane alkaloids scopolamine and atropine, which block muscarinic acetylcholine receptors to produce antispasmodic and CNS-depressant effects.

### Is Hyoscyamus muticus safe to consume or use as a supplement?

Hyoscyamus muticus is not safe for self-administration as a crude supplement due to the presence of high concentrations of scopolamine and atropine, which cause anticholinergic toxicity — symptoms include rapid heart rate, hallucinations, urinary retention, and potentially fatal respiratory depression — at doses not far above any putative therapeutic level. No standardized safe dose has been established for human use, and the plant is contraindicated in people with glaucoma, enlarged prostate, heart arrhythmias, and during pregnancy.

### What are the active compounds in Hyoscyamus muticus?

The plant contains two pharmacologically dominant alkaloids — scopolamine (13.79% of alkaloid fraction) and atropine (3.80%) — responsible for its anticholinergic effects, alongside an extensive phenolic profile led by chlorogenic acid at 17,108.3 µg/g, which is exceptionally high and drives potent antioxidant activity. Additional bioactive phenolics include protocatechuic acid, p-coumaric acid, rutin, rosmarinic acid, quercetin, luteolin, and hyperoside, with hyperoside showing the strongest urease inhibition by molecular docking (binding energy −7.9 kcal/mol).

### Has Hyoscyamus muticus been studied in clinical trials?

No human clinical trials evaluating Hyoscyamus muticus as a herbal preparation have been published as of current available literature; all evidence comes from in vitro phytochemical analyses, antioxidant assays, enzyme inhibition studies, and computational molecular docking. While the pharmacology of its isolated alkaloids (atropine and scopolamine) is extensively documented in clinical medicine, the behavior of the whole plant extract in human subjects — including safe dosing, bioavailability, and efficacy — remains entirely unstudied.

### Does Hyoscyamus muticus interact with any medications?

Yes, the tropane alkaloids in Hyoscyamus muticus carry serious drug interaction risks: the anticholinergic effects are significantly potentiated by antihistamines (e.g., diphenhydramine), tricyclic antidepressants (e.g., amitriptyline), antipsychotics, and bladder medications, increasing the risk of anticholinergic toxicity. It also antagonizes the prokinetic effects of drugs like metoclopramide and may have unpredictable interactions with CNS depressants including opioids, benzodiazepines, and anesthetics.

### Is Egyptian Henbane safe to use during pregnancy or while breastfeeding?

Egyptian Henbane should be avoided during pregnancy and breastfeeding due to its potent anticholinergic alkaloids (atropine and scopolamine), which can cross the placental barrier and enter breast milk, potentially causing harm to the fetus or infant. The tropane alkaloids present in Hyoscyamus muticus are known teratogens and can interfere with fetal development and neonatal nervous system function. Medical supervision and avoidance are strongly recommended for pregnant and lactating women.

### What is the difference between Egyptian Henbane and other Hyoscyamus species in terms of alkaloid content?

Hyoscyamus muticus is distinguished by its specific alkaloid profile, which includes atropine and scopolamine as dominant compounds, though the exact ratios vary by plant part and growing conditions compared to Hyoscyamus niger or Hyoscyamus albus. Egyptian Henbane typically contains lower overall alkaloid concentrations than H. niger but maintains similar pharmacological effects due to its bioactive tropane alkaloids. The regional cultivation of H. muticus in North Africa and the Middle East has selected for alkaloid patterns suited to traditional ethnomedicinal applications in those areas.

### Who should avoid Egyptian Henbane supplementation?

Individuals with glaucoma, urinary retention, cardiac arrhythmias, hyperthyroidism, or those taking anticholinergic medications should strictly avoid Egyptian Henbane due to the antagonistic effects of its atropine and scopolamine content on acetylcholine receptors. Elderly patients, children, pregnant and breastfeeding women, and those with gastrointestinal obstruction or myasthenia gravis are at particularly high risk for adverse effects. Individuals with a personal or family history of psychosis should also avoid this ingredient, as anticholinergic compounds can trigger or exacerbate psychiatric symptoms.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*